GenEditBio Secures Tens of Millions in USD in Series Angel and Pre-A Funding to Advance Next-Generation Gene Editing Platforms

VCBeat has learned that Beijing Yinzheng Gene Technology Co., Ltd. (hereinafter referred to as “Yinzheng Gene”), a gene-editing platform technology company, recentlyYinzheng Gene,GenEditBio）AnnouncementCompleted tens of millions of U.S. dollars in Angel and Pre-A round financing, this round of financing was led by Qiming Venture Partners, with follow-on investment from Optimas Capital; the funds raised will be used to support the companyDevelopment of next-generation gene-editing tools and rapid advancement of the product pipeline, along with the recruitment of industry experts and technical talent,and furtherStrengthen the Company’s R&D and Management Teams。

Yinzheng Gene, established in 2021 and headquartered in Beijing, is an internationally leading platform-based technology company specializing in gene editing. The company possesses globally advanced technologies with independent intellectual property rights.Off-Target Assessment Technology Platform, and"Dedicated to applying this platform's technology to develop safer and more precise gene-editing therapeutics"Currently, the company is engaged in the development and manufacturing of gene-editing drugs, with multiple in vivo gene-editing product lines in early-stage research and development.

Dr. Zheng Zongli, Founder of Yinzheng GeneWith over a decade of extensive international research experience in the field of gene editing, Dr. Zongli Zheng co-developed GUIDE-Seq, an off-target assessment method, during his postdoctoral fellowship at Harvard Medical School alongside Keith Joung (co-founder of Editas Medicine, Beam Therapeutics, Verve Therapeutics, and Pairwise Plants). GUIDE-Seq is currently one of the most widely used methods in the field. Dr. Zheng has achieved multiple globally leading research outcomes in areas such as off-target assessment, high-precision nucleic acid editing enzymes, and next-generation editing tools, and has published numerous related research articles in top-tier journals. All core team members of the company possess specialized academic backgrounds in gene editing technology and extensive experience in the international-level R&D of innovative drugs.

Yinzheng Gene FocusDevelop next-generation CRISPR-based gene editing tools to enhance editing efficiency and precision, reduce off-target effects, and establish a robust patent barrier.Meanwhile, the company is also developing a new generation of more precise and diverse gene-editing tools to strengthen its leading position in the field. Currently, the company has successfully developed a series of core foundational technologies, including a next-generation off-target assessment system and next-generation gene editors. These proprietary foundational gene-editing technologies and tools are at the global forefront, offering broad prospects for technological application and market commercialization, thereby significantly advancing development in this field.

Leveraging its underlying technological advantages, Yingzheng GeneFocusing on in vivo gene-editing therapeutics as the core R&D area, we have established a high-throughput drug screening platform and a comprehensive drug evaluation system.Establish partnerships with companies possessing advanced LNP delivery technologies,Develop LNP-based in vivo drug delivery systems.Meanwhile, the company continuously enhances its R&D and industrialization capabilities, establishing scalable manufacturing technologies and systems for in vivo gene-editing drug formulations, thereby enabling its product pipeline to rapidly advance from early-stage research to preclinical studies and clinical trials required for regulatory submission.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages ten U.S. dollar-denominated funds and six RMB-denominated funds, with total assets under management exceeding US$6.2 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in sectors such as TMT and Healthcare.

To date, Qiming Venture Partners has invested in more than 430 high-growth innovative companies, of which over 170 have achieved exits through listings on exchanges such as the New York Stock Exchange, NASDAQ, the Hong Kong Stock Exchange, the Taipei Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, as well as through mergers and acquisitions. More than 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

Fangyuan Capital, established in 2018, is a private equity investment firm specializing in life sciences, healthcare, and related sectors.

Optimas Capital is dedicated to identifying outstanding entrepreneurial teams with an innovative spirit and proactively discovering exceptional companies in niche sectors. Leveraging its extensive industry resources and operational expertise, the firm provides deep empowerment to its portfolio companies throughout their lifecycle—from inception to post-IPO development—accompanying them on their growth journey and helping them become distinguished enterprises with significant social impact and leading industry standing.

Currently, Optimas Capital manages two U.S. dollar-denominated biopharmaceutical funds and multiple single-asset funds. Its portfolio companies include Jacobio Pharmaceuticals (1167.HK), XtalPi, Deepwise Bio, and Yudao Bio.